Filing Flows

Filing Flows › Monte Rosa Therapeutics (GLUE) › Next earnings date

Monte Rosa Therapeutics (GLUE) earnings: beat the estimate

Monte Rosa Therapeutics (GLUE) reported on Nov 5, 2026 and beat the EPS estimate: $0.03 against −$0.20 (+114.9%). Revenue was $54.4M for Q3 2026, +326% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+114.9% vs estimate
Beat rate40%

The last report

Monte Rosa Therapeutics reported revenue of $54.4M for the third quarter 2026 (+326% Y/Y), net earnings $3.1M. How it makes money → · Every quarter →

Monte Rosa Therapeutics: EPS against the estimate, last 5 reportsMonte Rosa Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.35−$0.33Nov 25−$0.34−$0.55Mar 26−$0.38−$0.45May 26−$0.37−$0.43Aug 26−$0.20$0.03Nov 26
Latest (Nov 26): Estimate −$0.20, Reported $0.03.

Monte Rosa Therapeutics' latest quarter

Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Monte Rosa Therapeutics beat earnings?

Monte Rosa Therapeutics (GLUE) reported on Nov 5, 2026 and beat the EPS estimate: $0.03 against −$0.20 (+114.9%).

When does GLUE report earnings?

The next date is not set yet.

Does Monte Rosa Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.